IL2 and neoplasm: Administration of TCR.CoStAR-Td T cells from two independent donors alongside exogenous IL-2 led to significantly better control of tumor growth relative to Non-Td in donor 1 (Figure 4A, Supplementary Figure 3C) and Non-Td, CoStAR-Td, and TCR-Td treatment groups in donor 2 (Supplementary Figure 3C).